Upneeq™ (oxymetazoline hydrochloride ophthalmic solution 0.1%) is an ophthalmic drop which has acquired ptosis as an indication for its use. In response to concerns regarding the use of the drug by practitioners who may not be familiar with potentially serious neurological and orbital conditions associated with ptosis, the Academy, the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS), and the North American Neuro-Ophthalmology Society (NANOS) engaged with the Food and Drug Administration (FDA) to update the package insert for the product. The FDA has informed us that they agreed with our concerns and have approved an updated package insert that adds a new warning.
- Ophthalmologists Anticipate a School Year Marked by Complaints of Eye Strain
- AAO Update: Upneeq™ (oxymetazoline hydrochloride ophthalmic solution 0.1%)
- Ophthalmologists Urge Eye Protection for Recreational and Professional Sports
- Sixty Percent of Americans with Diabetes Skip Annual Sight-Saving Exams